Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA

Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA

Objectives This observational study compares the effectiveness of baricitinib (BARI), a targeted synthetic disease-modifying antirheumatic drug (tsDMARD), with alternative biological DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA), from a prospective, longitudinal cohort.Methods We compa...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Axel Finckh, Kim Lauper, Denis Mongin, Delphine S Courvoisier, Benoît Thomas P Gilbert, Clémentine Perrier, Romain Aymon, Cédric Laedermann, Ruediger Mueller
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	BMJ Publishing Group 2024-03-01
Sraith:	BMJ Open
Rochtain ar líne:	https://bmjopen.bmj.com/content/14/3/e072300.full

Míreanna comhchosúla

Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis
de réir: Axel Finckh, et al.
Foilsithe / Cruthaithe: (2021-07-01)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
de réir: Taylor, PC, et al.
Foilsithe / Cruthaithe: (2023)

Brief report: can COVID-19 infection trigger rheumatoid arthritis-associated autoimmunity in individuals at risk for the disease? A nested cohort study
de réir: Celine Lamacchia, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment
de réir: Caporali, R, et al.
Foilsithe / Cruthaithe: (2022)

Large language models for accurate disease detection in electronic health records: the examples of crystal arthropathies
de réir: Kim Lauper, et al.
Foilsithe / Cruthaithe: (2024-12-01)

Development and validation of a self-updating gout register from electronic health records data
de réir: Kim Lauper, et al.
Foilsithe / Cruthaithe: (2024-05-01)

Associations of regrets and coping strategies with job satisfaction and turnover intention: international prospective cohort study of novice healthcare professionals
de réir: Boris Cheval, et al.
Foilsithe / Cruthaithe: (2019-04-01)

Measuring ACPA in the general population or primary care: is it useful?
de réir: Axel Finckh, et al.
Foilsithe / Cruthaithe: (2020-02-01)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
de réir: Antonio Gasbarrini, et al.
Foilsithe / Cruthaithe: (2020-02-01)

COVID-19 Vaccination Rate under Different Political Incentive: A Counterfactual Trend Approach Using Nationwide Data
de réir: Denis Mongin, et al.
Foilsithe / Cruthaithe: (2023-06-01)

Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
de réir: Strand, V, et al.
Foilsithe / Cruthaithe: (2021)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
de réir: Juthamas Prawjaeng, et al.
Foilsithe / Cruthaithe: (2023-05-01)

Massive nodulous lesions on hands and feet in a RA patient and improvement under baricitinib treatment
de réir: Bernhard Manger, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Association between baseline haemoglobin levels and radiographic joint damage progression in patients with rheumatoid arthritis treated with baricitinib or standard of care
de réir: Moeller, B, et al.
Foilsithe / Cruthaithe: (2019)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
de réir: Kulveer Mankia, et al.
Foilsithe / Cruthaithe: (2022-04-01)

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2013)

PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs
de réir: Mart van de Laar, et al.
Foilsithe / Cruthaithe: (2024-05-01)

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2019)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
de réir: Yue Yang, et al.
Foilsithe / Cruthaithe: (2020-09-01)

Time to Publication and Time‐Lag Publication Bias for Randomized Trials on Connective Tissue Diseases
de réir: Denis Mongin, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Biologics in rheumatoid arthritis (RA) – recommendations for Swiss practice
de réir: BA Michel
Foilsithe / Cruthaithe: (2011-05-01)

Application of Baricitinib in Dermatology
de réir: Zhang J, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
de réir: Georg Schett, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial
de réir: Jos WR Twisk, et al.
Foilsithe / Cruthaithe: (2022-02-01)

Neighbourhood socio-economic vulnerability and access to COVID-19 healthcare during the first two waves of the pandemic in Geneva, Switzerland: A gender perspective
de réir: Denis Mongin, et al.
Foilsithe / Cruthaithe: (2022-04-01)

Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound
de réir: Giacomo Cozzi, et al.
Foilsithe / Cruthaithe: (2024-12-01)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
de réir: Marie Kostine, et al.
Foilsithe / Cruthaithe: (2022-10-01)

The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
de réir: Renaud Felten, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Response to: “Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation” by Masi and Fleischmann
de réir: Debbie M. Boeters, et al.
Foilsithe / Cruthaithe: (2020-03-01)

Baricitinib for the treatment of rheumatoid arthritis
de réir: Ivan Urits, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases
de réir: Celine Lamacchia, et al.
Foilsithe / Cruthaithe: (2023-05-01)

A SURVEY OF DMARD PREFERENCES OF UK RHEUMATOLOGISTS
de réir: Douglas, K, et al.
Foilsithe / Cruthaithe: (2003)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
de réir: Mysler E, et al.
Foilsithe / Cruthaithe: (2021-06-01)

The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
de réir: Jie Chang, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan
de réir: Der-Yuan Chen, et al.
Foilsithe / Cruthaithe: (2019-10-01)

ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation
de réir: Debbie M. Boeters, et al.
Foilsithe / Cruthaithe: (2019-05-01)

Correction to: Response to: “Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation” by Masi and Fleischmann
de réir: Debbie M. Boeters, et al.
Foilsithe / Cruthaithe: (2020-05-01)

Periodontitis in First Degree-Relatives of Individuals With Rheumatoid Arthritis: A Short Narrative Review
de réir: Alkisti Zekeridou, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
de réir: Coates, L, et al.
Foilsithe / Cruthaithe: (2017)

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
de réir: Fautrel, B, et al.
Foilsithe / Cruthaithe: (2019)